Hepatic veno-occlusive disease: Pathogenesis, diagnosis and treatment

Current Opinion in Hematology

Volumn 10, Issue 6, 2003, Pages 451-462

  Wadleigh, Martha ^a   Ho, Vincent ^a   Momtaz, Parisa ^a   Richardson, Paul ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Hematopoietic; Hepatic; High dose endothelial injury; Risk factors; Stem cell transplant; Veno occlusive disease

Indexed keywords

ANTITHROMBIN III; DEFIBROTIDE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENTOXIFYLLINE; PROSTAGLANDIN E; STEROID; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ANTIBODY;

CELL DAMAGE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOFILTRATION; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; JAUNDICE; LIVER SINUSOID; LIVER TRANSPLANTATION; LIVER VEIN OBSTRUCTION; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; WEIGHT GAIN;

ENDOTHELIUM, VASCULAR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; RISK FACTORS;

EID: 0242267092     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200311000-00010     Document Type: Review

References (148)

1. McDonald GB, Sharma P, Matthews DE, et al.: Venoocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984, 4:116-122.
2. Bearman SI: The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995, 85:3005-3020.
3. Richardson PG, Guinan EC: The pathology, diagnosis and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol 1999, 107:485-493.
4. Lee JL, Gooley T, Bensinger W, et al.: Venocclusive disease of the liver after high-dose chemotherapy with alkylating agents: incidence, outcome and risk factors. Hepatology 1997, 26:149A.
5. Carreras E, Bertz H, Arcese W, et al.: Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998, 92:3599-3604.
6. McDonald GB: Venocclusive disease of the liver following marrow transplantation. Marrow Transplantation Reviews 1993, 3:49-56.
7. McDonald GB, Hinds MS, Fisher LD, et al.: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Int Med 1993, 118:255-267.
8. Holler E, Kolbe HJ, Moller A, et al.: Increased serum levels of TNFa precede major complications of bone marrow transplantation. Blood 1990, 75:1011-1016.
9. Krenger W, Hill GR, Ferrara JLM: Cytokine cascades in acute graft-versus-host disease. Transplantation 1997, 64:553-558.
10. Baglin TP: Veno-occlusive disease of the liver complicating bone marrow transplantation. Bone Marrow Transplant 1994, 13:1-4.
11. DeLeve L, Shulman HM, McDonald GB: Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002, 22:27-42.
12. DeLeve LD: Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology 1996, 24:830-837.
13. Shulman HM, Fisher LB, Schoch HG, et al.: Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology 1994, 19:1171-1180.
14. Bearman SI: Don't GO to VOD. Blood 2003, 102:1561a.
15. Shirai M, Nagashima K, Iwasaki S, et al.: A light and scanning electron microscopic study of hepatic veno-occlusive disease. Acta Pathol Jpn 1987, 37:1961-1971.
16. Shulman HM, McDonald GB, Matthews D, et al.: An analysis of hepatic venoocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980, 79:1178-1191.
17. Shulman HM, Gown AM, Nugent DJ: Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987, 127:549-558.
18. Traber PG, Chianale J, Gumucio JJ: Physiologic significance and regulation of hepatocellular heterogeneity. Gastroenterology 1988, 95:1130-1143. [see comments].
19. el Mouelhi M, Kauffman FC: Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver. Hepatology 1986, 6:450-456.
20. Deleve LD: Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994, 268:1261-1270.
21. Teicher BA, Crawford JM, Holden SA, et al.: Glutathione monoethyl ester can selectively protect liver from high-dose BCNU or cyclophosphamide. Cancer 1988, 62:1275-1281.
22. Grochow LB: Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993, 20:18-25.
23. Hassan M, Oberg G, Bekassy AN, et al.: Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991, 28:130-134.
24. Schuler U, Schroer S, Kuhnle A, et al.: Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994, 14:759-765.
25. Yeager AM, Wagner JE Jr, Graham ML, et al.: Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992, 80:2425-2428.
26. Slattery JT, Kalhorn TF, McDonald GB, et al.: Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996, 14:1484-1494.
27. DeLeve LD: Glutathione defense in non-parenchymal cells. Semin Liver Dis 1998, 18:403-413.
28. McDonald GB, Slattery JT, Bouvier ME, et al.: Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003, 101:2043-2048.
29. Wang X, Kanel GC, DeLeve LD: Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology 2000, 31:428-434.
30. Ringden O, Remberger M, Lehmann S, et al.: N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2000, 25:993-996.
31. Catani L, Gugliotta L, Vianelli N, et al.: Endothelium and bone marrow transplantation. Bone Marrow Transplant 1996, 17:277-280.
32. Salat C, Holler E, Reinhardt B, et al.: Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 1994, 14:747-750.
33. Salat C, Holler E, Kolbe HJ, et al.: Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant. Blood 1997, 89:2184-2188.
34. Richardson P, Krishnan A, Wheeler C, et al.: Elevation of PAI-1 levels in BMT-associated VOD and changes seen with the use of defibrotide. Blood 1996, 88:458a.
35. Richardson P, Hoppensteadt D, Elias A, et al.: Elevation of tissue factor pathway inhibitor [TFPI], thrombomodulin [TM] and plasminogen activator inhibitor-1 [PAI-1] levels in stem cell transplant [SCT]-Associated veno-occlusive disease [VOD] and changes seen with the use of defibrotide. Blood 1997, 90:219a.
36. Richardson PG, Hoppensteadt DA, Elias AD, et al.: Elevation of endothelial stress products and trends seen in patients with severe veno-occlusive disease treated with defibrotide. Thromb Haemost 1999, 628.
37. Nurnberger W, Michelmann I, Burdach S, et al.: Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998, 76:61-65.
38. Sato Y, Asada Y, Hara S, et al.: Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology 1999, 34:66-70.
39. Bianchi M, Tracey KJ: The role of TNF in complications of marrow transplantation. Marrow Transplantation Reviews 1993-1994, 3:57-61.
40. Scrobohaci ML, Drouet L, Monem-Mansi A, et al.: Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res 1991, 63:509-519.
41. Ferra C, de Sanjose S, Gallardo D, et al.: IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica 1998, 83:1082-1087.
42. Schots R, Kaufman L, Van Riet I, et al.: Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant 1998, 22:79-85.
43. Anscher MS, Peters WP, Reisenbichler H, et al.: Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993, 328:1592-1598.
44. Eltumi M, Trivedi P, Hobbs J: and e. al., Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropepide of type III procollagen. Lancet 1993, 342:518-521.
45. Park J-D, Yasui M, Yoshimoto T, et al.: Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 1997, 19:915-920.
46. Rio B, Bauduer F, Arrago JP, Zittoun R: N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 1993, 11:471-472.
47. Heikinheimo M, Halila R, Fasth A: Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Blood 1994, 83:3036-3040.
48. Collins PW, Gutteridge CN, O'Driscoll A, et al.: von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant 1992, 10:499-506.
49. Harper PL, Jarvis J, Jennings I, et al.: Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 1990, 5:39-42.
50. Haire WD, Ruby EI, Gordon BG, et al.: Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA 1995, 274:1289-1295.
51. Faioni EM, Krachmalnicoff A, Bearman SI, et al.: Naturally occuring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993, 81:3458-3462.
52. Sudhoff T, Heins M, Sohngen D, et al.: Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation. Eur J Haematol 1998, 60:106-111.
53. Oh H, Tahara T, Bouvier M, et al.: Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease of the liver. Bone Marrow Transplant 1998, 22:675-679.
54. Nevill TJ, Barnett MJ, Klingemann H-G, et al.: Regimen-related toxicity of busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991, 9:1224-1232.
55. Matute-Bello G, McDonald GD, Hinds MS, et al.: Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998, 21:1125-1130.
56. Reiss U, Cowan M, McMillan A, Horn B: Hepatic venooclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002, 24:706-709.
57. Hagglund H, Remberger M, Klaesson S, et al.: Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998, 92:4568-4572.
58. Soiffer R, Dear K, Rabinowe SN, et al.: Hepatic dysfunction follwoing T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991, 52:1014-1019.
59. Moscardo F, Sanz GF, De la Rubia J: Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34+ positive selection. Bone Marrow Transplant 2001, 27:983-988.
60. Ringden O, Ruutu T, Remberger M, et al.: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a Report from the Nordic Bone Marrow Transplantation Group. Blood 1994, 83:2723-2730.
61. Styler MJ, Crilley P, Biggs J: Hepatic dysfunction following busulfan and cyclophosphamide myeloblation: a retrospective, multicenter analysis. Bone Marrow Transplant 1996, 18:171-176.
62. Rozman C, Carreras E, Qian C, et al.: Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996, 17:75-80.
63. Fisher DC, Vredenburgh JJ, Petros WP, et al.: Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant 1998, 21:117-122.
64. Strauer BE, Brehm M, Zeus T, et al.: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2003, in press.
65. Korbling M, Katz RL, Khanna A, et al.: Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 2002, 346:738-746.
66. Tack DK, Letendre L, Kamath P, et al.: Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant 2001, 28:895-897.
67. McDonald GB: Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzmab ozogamicin (mylotarg ®). Clin Lymphoma 2002, 2:S35-S39.
68. Wadleigh M, Richardson P, Zahrieh D, et al.: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003, 102:1578-1582.
69. Sievers EL, Larson R, Estey E, et al.: Final report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematopoietic stem cell transplantation. Blood 2002, 100:89a.
70. Rajvanshi P, Shulman HM, Sievers EL, et al.: Hepatic Sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002, 99:2310-2314.
71. Strasser SI, McDonald GB: Gastrointestinal and hepatic complications. In Hematopoietic Cell Transplantation. edn 2. Edited by Forman SJ, Blume KG, Thomas ED. Oxford: Blackwell Publishing; 1998.
72. Jones RJ, Lee KSK, Beschorner WE, et al.: Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987, 44:778-783.
73. Stockschlaeder M, Storb R, Pepe M, et al.: A pilot study of low dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br J Haematol 1992, 80:49-54.
74. Christians U, Spiekermann K, Bader A, et al.: Cyclosporine metabolite pattern in blood from patients with acute GVHD after BMT. Bone Marrow Transplant 1993, 12:27-33.
75. Thaler M, Pastiaka B, Shawker TH, et al.: Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988, 108:88-100.
76. Carreras E, Granena A, et al.: On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993, 66:77-80.
77. Brown BP, Abu-Yousef M, Farner R, et al.: Doppler sonography: A noninvasive method for evaluation of hepatic venocclusive disease. AJR Am J Roentgenol 1990, 154:721-724.
78. Hosoki T, Kuroda C, Tokunaga K, et al.: Hepatic venous outflow obstruction: Evaluation with pulsed duplex sonography. Radiology 1989, 170:733-737.
79. Nicolau C, Concepcio B, Carreras E, et al.: Sonographic diagnosis and hemodynamic correlation in veno-occlusive disease of the liver. J Ultrasound Med 1993, 12:437-440.
80. Sonneveld P, Lameris JS, Cornelissen J, et al.: Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment. Bone Marrow Transplant 1998, 21:731-734.
81. van den Bosch MA, van Hoe L: MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation. Eur Radiol 2000, 10:1290-1293.
82. Carreras E, Granena A, Navasa M, et al.: Transjugular liver biopsy in BMT. Bone Marrow Transplant 1993, 11:21-26.
83. Shulman HM, Gooley T, Dudley MD, et al.: Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995, 59:1015-1022.
84. Bearman SI, Anderson GL, Mori M, et al.: Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993, 11:1729-1736.
85. Barrett J, Childs R: Non-myeloblative stem cell transplants. Br J Haematol 2000, 111:6-17.
86. Maris M, Sandmaier BM, Maloney DG, et al.: Non-myeloblative hematopoietic stem cell transplantation. Transfus Clin Biol 2001, 8:231-234.
87. Tse WT, Beyer W, Pendleton JD, et al.: Genetic polymorphisms in glutathione s-transferase and plasminogen activator inhibitor and risk of veno-occlusive disease (VOD). Blood 2000, 96:390a.
88. Poonkuzhali S, Vidya S, Shaji RV, et al.: Glutathione S-transferase gene polymorphism and risk of major undergoing allogeneic bone marrow transplantation. Blood 2001, 98:852a.
89. Haire WD, Cavet J, Pavletic SZ, et al.: Tumor necrosis factor d3 allele predicts for organ dysfunction after allogeneic blood stem cell transplantation (ABSCT). Blood 2000, 96:584a.
90. Allen JR, Carstens LA, Katagiri GJ: Hepatic veins of monkeys with veno-occlusive disease. Sequential ultrastructural changes. Arch Pathol 1969, 87:279-289.
91. Ohashi K, Tanabe J, Watanabe R, et al.: The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000, 64:32-38.
92. Essell JH, Schroeder MT, Harman GS, et al.: Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:975-981.
93. Ruutu T, Eriksson B, Remes K, et al.: Ursodiol prevention of hepatic complications in allogeneic stem cell transplantation: results of a prospective, randomized, placebo-controlled trial [abstract]. Bone Marrow Transplant 1999, 23:756.
94. Jonas CR, Puckett AB, Jones DP, et al.: Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr 2000, 72:181-189.
95. Goringe AP, Brown S, O'Callaghan U, et al.: Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant 1998, 21:829-832.
96. Khoury H, Adkins D, Trinkaus K, et al.: Treatment of hepatic veno-occlusive disease with high-dose corticosteroids: an update on 28 stem cell transplant recipients. Blood 1998, 92:1132a.
97. Ferra C, Sanjose S, Lastra CF, et al.: Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant 1997, 20:1075-1080.
98. Clift RA, Bianco JA, Appelbaum FR, et al.: A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993, 82:2025-2030.
99. Attal M, Huguet F, Rubie H: Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992, 79:2834-2840.
100. Bearman SI, Hinds MS, Wolford JL: A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990, 5:407-411.
101. Marsa-Vila L, Gorin NC, Laporte JP: Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991, 47:346-352.
102. Budinger MD, Bouvier M, Shah A, , et al.: Results of a phase 1 trial of antithrombin III as prophylaxis in bone marrow transplant patients at risk for veno-cclusive disease [abstract]. Blood 1996, 88:172a.
103. Forrest DL, Thompson K, Dorcas VG, et al.: Low molecular weight heparin for the prevention of veno-occlusive disease (VOD) after hematopoietic stem cell transplantations prospective phase II study. Bone Marrow Transplant 2003, 31:1143-1149.
104. Lee JH, Lee KH, Choi JS, et al.: Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment. J Korean Med Sci 1996, 11:118-126.
105. Or R, Nagler A, Shpilberg O, et al.: Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996, 61:1067-1071.
106. Vaughan DE, Plavin SR, Schafer AI: PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood 1989, 73:1213-1217.
107. Gluckman E, Jolivet I, Scrobohaci ML: Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990, 74:277-281.
108. Schriber JR, Milk BJ, Baer MR: A randomized phase II trial comparing heparin (Hep) +/-prostaglandin E1 (PG) to prevent hepatotoxicity (HT) following bone marrow transplantation (BMT): preliminary results. Blood 1996, 88:1642.
109. Bearman SI, Shen D, Hinds MS, et al.: A phase I/II study of prostaglandin E1 for the prevention of hepatic venoocclusive disease after bone marrow transplantation. Br J Haematol 1993, 84:724-730.
110. Rubenfeld GD, Crawford SW: Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: A case for evidence-based guidelines. Ann Intern Med 1996, 125:625-633.
111. Bearman SI, Shuhart MC, Hinds MS, , et al.: Recombinant human tissue plasminogen activator for the treatment of established severe venoocclusive disease of the liver after bone marrow transplantation. Blood 1992, 80:2458-2462.
112. Leahey AM, Bunin NJ: Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant 1996, 17:1101-1104.
113. Richardson P, Bearman SI: Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. Leuk Lymphoma 1998, 31:267-277.
114. Richardson P, Guinan E: Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol 2001, 106:57-68.
115. Bearman SI, Lee JL, Baron AE, , et al.: Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997, 89:1501-1506.
116. Haire WD, Stephens LC, Ruby EI: Antithrombin III (AT3) treatment of organ dysfunction during bone marrow transplantation (BMT)-results of a pilot study [abstract]. Blood 1996, 88:458a.
117. Morris JD, Harris RE, Hashmi R, et al.: Antithrombin-III for the treatment of chemotherapy - induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997, 20:871-878.
118. Ibrahim A, Pico JL, Maraninchi D, et al.: Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1. Bone Marrow Transplant 1991, 7:53.
119. Bianchi G, Barone D, Lanzarotti E, et al.: Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993, 238:327-334.
120. Eissner G, Multhoff G, Gerbitz A, et al.: Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002, 100:334-340.
121. Bracht F, Schror K: Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun 1994, 200:933-936.
122. Berti F, Rossoni G, Biasi G, et al.: Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins. Prostaglandins 1990, 40:337-350.
123. Coccheri S, Biagi G: Defibrotide. Cardiovascular Drug Review 1991, 9:172-196.
124. Fareed J: Modulation of endothelium by heparin and related polyelectrolytes. In Advances in Vascular Pathology. Edited by Nicolaides A, Novo S. Amsterdam: Elsevier; 1997.
125. Zhou Q, Chu X, Ruan C: Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 1994, 71:507-510.
126. Palmer KJ, Goa KL: Defibrotide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993, 45:259-294.
127. Coccheri S, Biagi G, Legnani C, et al.: Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 1988, 35:151-156.
128. Ulutin ON: Antithrombotic effect and clinical potential of defibrotide. Sem Thrombosis and Hemostasis 1993, 19:186-191.
129. Jamieson A, Alcock P, Tuffin DP: The action of polyanionic agents defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat. Fibrinolysis 1996, 10:27-35.
130. Bonomini V, Vangelista A, Frasca GM: A new antithrombotic agent in the treatment of acute renal failure due to hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura [letter]. Nephron 1984, 37:144.
131. Viola F, Marubini S, Coccheri G, et al.: Improvement of walking distance by defibrotide in patients with intermittent claudication: results of a randomized, placebo-controlled study (the DICLIS study). Thromb Haemost 2000, 83:672-677.
132. Falanga A, Marchetti M, Vignoli A, et al.: Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cell macro-and micro-vessels. Blood 2000, 96:53a.
133. Falanga A, Vignoli A, Marchetti M, et al.: Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003, 17:1636-1642.
134. Richardson PG, Elias AD, Krishnan A, et al.: Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998, 92:737-744.
135. Abecasis M, Ferreira I, Guimaraes A, et al.: Defibrotide as salvage therapy for hepatic veno-occlusive disease (VOD) [abstract]. Bone Marrow Transplant 1999, 23:749.
136. Salat C, Pihusch R, Fries S, et al.: Successful treatment of veno-occlsive disease with defibrotide - a report of two cases [abstract]. Bone Marrow Transplant 1999, 23:757.
137. Zinke W, Neumeister P, Linkesch W: Defibrotide- an approach in the treatment of severe veno-occlusive disease? [abstract]. Bone Marrow Transplant 1999, 23:760.
138. Jenner MJ, Micallef IN, Rohatiner AZ, et al.: Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide. Med Oncol 2000, 17:333-336.
139. Chopra R, Eaton JD, Grassi A, et al.: Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000, 111:1122-1129.
140. Richardson P, Murakami C, Jin Z, et al.: Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high risk population and factors predictive of outcome. Blood 2002, 100:4337-4343.
141. Richardson P, Warren D, Momtaz P, et al.: Multi-institutional phase ii randomized dose finding study of defibrotide in patients with severe veno-occlusive disease and multi-system organ failure post stem cell transplantation: promising response rate without significant toxicity in a high risk population. Blood 2001, 98:853a.
142. Chanlandon Y, Roosnek E, Helg C, et al.: Efficient prophylaxis with defibrotide for hepatic veno-occlusive disease after allogeneic stem cell transplantation (SCT). Blood 2002, 100:111a.
143. Joshi R, Kerridge I, Grace S, et al.: Prophylactic defibrotide for the prevention of hepatic veno-occlusive disease (VOD) in hematopoietic stem cell transplantation (HSCT). Blood 2002, 100:413a.
144. Schlitt HJ, Tischler HJ, Ringe B, et al.: Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation-clinical and immunological considerations. Bone Marrow Transplant 1995, 16:473-478.
145. Fried MW, Connaghan DG, Sharma S, et al.: Trans jugular intrahepatic protosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996, 24:588-591.
146. Smith FO, Johnson MS, Scherer LR, et al.: Transjugular intrahepatic portosystemic shunting (TIPS) for the treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant 1996, 18:643-646.
147. Alvarez R, Banares R, Casariego J, et al.: Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation. Gastroenterol Hepatol 2000, 23:177-180.
148. Tefferi A, Kumar S, Wolf R, et al.: Charcoal hemofiltration for hepatic veno-occulsive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 28:997-9 99.